Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States

Journal of Medical Economics

Volumn 13, Issue 1, 2010, Pages 33-41

  Yuan, Yong ^a   Trivedi, Digisha ^a   MacLean, Ross ^a   Rosenblatt, Lisa ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Arthritis; Cost effectiveness; Tumor necrosis factor alpha

Indexed keywords

ABATACEPT; METHOTREXATE; RITUXIMAB;

ARTICLE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SIMULATION; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; COST-BENEFIT ANALYSIS; DISABILITY EVALUATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOCONJUGATES; IMMUNOLOGIC FACTORS; METHOTREXATE; MIDDLE AGED; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RHEUMATIC FEVER; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; YOUNG ADULT;

EID: 77149131276     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903508021     Document Type: Article

References (45)

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(Suppl 1):1-12
2. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271
3. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept inpatients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 20 2006;144:865-76
4. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
5. Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20-30
6. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multicentre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103
7. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123
8. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
9. Orencia [package insert]: Bristol-Myers Squibb, 2008.
10. Rituxan [package insert]: 2008
11. Kobelt G. Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl 3):iii35-39
12. Drummond MF, Schwartz JS, Jonsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008;24:244-258
13. Vera-llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 2008;47:535-541
14. Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004;43:62-72
15. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002
16. Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol 2008;35:1745-1753
17. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-799
18. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221-1232
19. Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-793
20. Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-2327
21. Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-1165
22. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
23. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of retreatment in initial nonresponders versus initial responders. Arthritis Rheum 2008;58:3657-3664
24. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258
25. Halpern EF, Weinstein MC, Hunink MG, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314-322
26. Goldie SJ. Chapter 15: Public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monogr 2003;102-110
27. Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997;17:483-489
28. Doan QV, Chiou CF, Dubois RW. Review of eight pharmaco-economic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006;12:555-569
29. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-408
30. Clark W, Jobanputra P, Barton P, Burls A. Technology assessment report commissioned by the HTA programme on behalf of the National Institute for Clinical Excellence: the clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults. 2003; http://eprints.bham.ac.Uk/32/ 1/Clark-W,-Anakinra.pdf
31. Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-110
32. Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-335
33. Welsing PM, Severens JL, Hartman M, et al. Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004;51:964-973
34. Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-1179
35. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-1354
36. Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939-946
37. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784
38. Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford) 2005;44(Suppl 4):ivl8-22
39. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-554
40. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-963
41. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-1089
42. Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009;36:736-742
43. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-38108
44. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-221
45. Pincus T, Yazici Y, van Vollenhoven R. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for long-term observations in standard care to complement clinical trials J Rheumatol 2006;33:2372-2375